Pregnancy and Use of Psychoactive Substances: The Influence of Representations of Care on Care.

Pregnancy Clinical Trial

— ADDGEST  

Official title:

Pregnancy and Use of Psychoactive Substances: The Influence of Representations of Care on Care.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03567070
• Other study ID #: 17-050
• Status: Completed
• Phase: N/A
• Start date: March 17, 2017
• Est. completion date: June 12, 2018

Study information

• Verified date: June 2018
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is observed that pregnant women using psychoactive substance (s) have a more random and more accidental pregnancy follow-up than women with no addictive problems.

The consumption approach can be either omitted during the pregnancy monitoring, or entrusted to the course or more often in late pregnancy or occurs more brutally during delivery at the time of complications (neonatal or obstetric). In this context, health professionals are looking for levers that allow women to take appropriate care quickly.

This difficulty of access to care questions us and all the more because the time of the pregnancy is a moment of important psychic reorganization conducive to modify its habits, to change its glance on its consumptions and thus to start a care concerning addiction.

Invesigators hypothesize that this population has less access to medical care during pregnancy for fear of stigmatization by the health care provider.

Invesigators propose a multicenter qualitative study based on individual clinical interviews to collect the testimony of women who used psychoactive substance (s) during their pregnancy.

The purpose of this work is to identify ways to improve the multidisciplinary medical management of these women by focusing on the representations they can make care of.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: June 12, 2018
• Est. primary completion date: August 24, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major patients

• Pregnant or having given birth since <28 days

• Having used (whether declared or discovered incidentally) - regardless of the amount of psychoactive substance (s) during pregnancy: alcohol, and / or heroin or OST, and / or cannabis, and / or psychostimulants (cocaine, ecstasy, amphetamines)

• Followed or not in addictology during pregnancy

Exclusion Criteria:

• Minor patients

• Patients under legal protection (guardianship, guardianship)

• Linguistic obstacle

• Psychiatric pathology decompensated at the time of the meeting

• Women who only used tobacco regularly during pregnancy

• Women who have only regularly used psychoactive drugs and / or licit opiates (excluding prescription replacement products) during pregnancy

Related Conditions & MeSH terms

• Pregnancy

Intervention

Other:
• qualitative study based on an individual clinical interview
qualitative study based on an individual clinical interview

Locations

Country	Name	City	State
France	Caen University Hospital	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	individual clinical interview	qualitative study based on an individual clinical interview	baseline